BDA.AX - Bod Australia Limited

ASX - ASX Delayed price. Currency in AUD

Bod Australia Limited

377 New South Head Road
Level 1
Double Bay, NSW 2028
61 2 9199 5018

SectorConsumer Defensive
IndustryHousehold & Personal Products
Full-time employees

Key executives

NameTitlePayExercisedYear born
Ms. Joanne PattersonCEO, Director & Member of Medical Advisory Board273.75kN/AN/A
Mr. Craig WellerCOO & Member of Medical Advisory Board273.75kN/AN/A
Mr. George LiveryExec. ChairmanN/AN/A1967
Dr. Adele HosseiniChief Scientific Officer & Member of Medical Advisory BoardN/AN/AN/A
Mr. Stephen ThompsonExec. DirectorN/AN/AN/A
Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


BOD Australia Limited operates as a developer, manufacturer, distributor, and marketer of plant-based medicinal cannabis, health and supplement products, and cosmetic solutions primarily in Australia. Its medicines portfolio includes Enterofytol for treating irritable bowel syndrome; and SediStress, which is used for the reduction of stress and anxiety. The company distributes its products through a channel network of approximately 900 pharmacies. It offers products under the SediStress, BIOEFFECT, PINPOINT, Flexofytol, Enterofytol, MamaCare, and Pommade Devine brands. Bod Australia Limited has a research collaboration agreement with Cannabis Access Clinics. The company is based in Double Bay, Australia.

Corporate governance

Bod Australia Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.